Market Overview

UPDATE: MLV & Co. Downgrades Dynavax Technologies to Hold Following Management Meetings

Related DVAX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
William Blair's Top BioPharma Stock Picks For Q1 2015
Oversight board recommends continuing Heplisav-B Phase 3 trial (Seeking Alpha)

In a report published Monday, MLV & Co. downgraded its rating on Dynavax Technologies Corporation (NASDAQ: DVAX) from Buy to Hold.

MLV noted, “After months of DVAX stock volatility and speculation as to what the immediate future of Dynavax's lead product candidate, HEPLISAV, would be, the FDA sent the company a complete response letter (CRL) regarding the prophylactic hepatitis B vaccine. This follows a vote to not approve HEPLISAV by the Vaccines and Related Biological Products Advisory Committee (AdCom) on November 15, 2012. We spoke with Dynavax management about the FDA decision and the options the company may pursue for HEPLISAV. Dynavax filed its Biologics License Application (BLA) with the FDA on April 26, 2012, for healthy adults between the ages of 18 and 70, and was planning to file a supplemental BLA for patients with chronic kidney disease (CKD) who are at increased risk of HBV and are unprotected by current vaccines following an initial approval. An application to the EMA for both healthy adults and CKD patients that was filed on July 24, 2012, remains on track and may lead to European approval by 1Q:14.”

Dynavax Technologies Corporation closed on Friday at $2.97.

Latest Ratings for DVAX

Nov 2013McNicoll Lewis VlakUpgradesHoldBuy
Nov 2013JefferiesReiteratesBuy
Jun 2013JefferiesMaintainsBuy

View More Analyst Ratings for DVAX
View the Latest Analyst Ratings

Posted-In: MLV & Co.Analyst Color Downgrades Analyst Ratings


Related Articles (DVAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content